Bloom, M., Bock, J., Duttaroy, A., Grzegorzewski, K., Moore, P., Ou, Y., Wojcik, S., Zhou, X. and Bell, A.C. (2003) Albugon Fusion Protein: A Long-Acting Analog of GLP-1 That Provides Lasting Antidiabetic Effect in Animals (Abstract). Diabetes, 52, A112.

has been cited by the following article:

• TITLE: Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?

  AUTHORS: Lis Marina de Mesquita Araújo, Sumaya Feguri, Thereza Lopes de Oliveira, Fernanda Batista Pedrosa, Rodrigo Garcez Guimarães, Larissa Bianca Paiva Cunha de Sá, Denise Rosso Tenório Wanderley Rocha, Alberto Krayyem Arbex

  KEYWORDS: Diabetes, GLP-1 Receptor Agonists, Glycemic Control, Extra Glicemic Effects, Weight Loss, Cardiovascular Risk

  JOURNAL NAME: Open Journal of Endocrine and Metabolic Diseases, Vol.6 No.1, January 21, 2016

  ABSTRACT: GLP-1 receptor agonists are approved for the treatment of type 2 diabetes, and more recently for obesity treatment.The glucagon-like-peptide-1 (GLP-1) is a glucose dependent hormone produced by intestinal cells, which is involved in insulin secretion and glucagon suppression. This hormone controls glucose plasma levels and reduces food intake. Additional effects were reported in slowing gastric emptying and in inducing satiety.In clinical practice, theGLP-1 receptor agonistsareassociated with significant reductions in glycosylated hemoglobin (HbA1c) and weight loss,despite showing a low risk of hypoglycemia.Beneficial effects have also been observed on blood pressureand lipid profile.The most common side effects associated with GLP-1 receptor agonists are gastro-intestinal motility disorders, such as nausea, vomiting and diarrhea, which are not associated withlong-term health risks. Therefore, GLP-1 receptor agonists represent a relevant medication for type 2 diabetes, whose benefits may go far beyond glycemic control.